Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
221 hedge funds and large institutions have $4.03B invested in Blueprint Medicines in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 74 increasing their positions, 77 reducing their positions, and 24 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
42% more capital invested
Capital invested by funds: $2.84B → $4.03B (+$1.19B)
29% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 24
3% more funds holding
Funds holding: 214 → 221 (+7)
0.28% more ownership
Funds ownership: 105.31% → 105.59% (+0.28%)
4% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 77
53% less call options, than puts
Call options by funds: $17.7M | Put options by funds: $37.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$97.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$36.7M |
| 3 |
Alkeon Capital Management
New York
|
+$32.2M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$27.2M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$22.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$115M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$17.3M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$16.5M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$15M |
| 5 |
State Street
Boston,
Massachusetts
|
-$13.7M |
BPMC Hedge Fund Activity: Q2 2023 in Review
221 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q2 2023, worth a combined $4.03B — up 42% from $2.84B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new BPMC positions and 24 closed out — a net gain of 7 holders — while 74 added to existing stakes and 77 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $97.8M. The largest seller was Fidelity Investments, cutting an estimated $115M.
- 221 institutional investors held Blueprint Medicines (BPMC) as of Q2 2023, up from 214 in Q1 2023.
- Funds reported $4.03B of Blueprint Medicines stock for Q2 2023, up 42% quarter-over-quarter.
- 31 funds opened new Blueprint Medicines positions in Q2 2023 and 24 closed out, a net change of +7 holders.
- The largest Blueprint Medicines buyer in Q2 2023 was EcoR1 Capital, an estimated $97.8M added.
- The largest Blueprint Medicines seller in Q2 2023 was Fidelity Investments, an estimated $115M sold.
Based on aggregated 13F filings for Q2 2023.